aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-17 20:45Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr plummeted by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Case Details - The complaint alleges that aTyr provided overly positive statements while concealing material adverse facts about Efzofitimod [2] - The EFZO-FIT study's failure to meet its primary endpoint was disclosed during an investor call on September 15, 2025, prompting the company to engage with the FDA for future steps [2] Next Steps - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]